NCT00711776 is a Phase 1 clinical trial of New formulation in Herpes Labialis, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00711776?

NCT00711776 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00711776?

Interventions in NCT00711776: New formulation, Current formulation.

What condition does NCT00711776 study?

NCT00711776 studies Herpes Labialis.

Is NCT00711776 still recruiting?

NCT00711776 is currently completed. Last updated 31 August 2018.

Last reviewed 2018-08-31 · How we verify

NCT00711776

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers

Completed Phase 1 Last updated 31 August 2018

What this trial tests

Phase 1 trial testing New formulation in Herpes Labialis in 27 participants. Completed in 17 August 2008.

Timeline

10 April 2008

Primary endpoint
17 August 2008

17 August 2008

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	10 April 2008
Primary completion	17 August 2008
Estimated completion	17 August 2008
Sites	1 location across Japan

Drugs / interventions tested

New formulation — full drug profile →
Current formulation

Conditions studied

Herpes Labialis — all drugs for Herpes Labialis →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 20 to 55, male only, with Herpes Labialis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to show bioequivalence between Current and New formulation of Aciclovir cream 5% in keratin layer of the epidermis in Japanese Subjects

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Herpes Labialis

Currently open trials in the same condition.

NCT01306084 — Viral Infections in Healthy and Immunocompromised Hosts · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00711776 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 31 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00711776.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing